Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.45 |
| ▸ | CNR1 | P21554 | 7/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8438876 | 0.94 | CNR2 (0.42) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL8438874 | 0.94 | CNR2 (0.42) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL26624981 | 0.90 | CNR2 (0.41) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL15256903 | 0.86 | ALDH1A1 (0.46) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL15879127 | 0.86 | CNR2 (0.39) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL31635596 | 0.86 | CNR2 (0.39) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL15305056 | 0.86 | CNR2 (0.39) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL15879130 | 0.86 | CNR2 (0.39) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL732601 | 0.84 | ALDH1A1 (0.41) | CNR2CNR1TRPA1TRPV1ALDH1A1 | |
| SCHEMBL10282163 | 0.84 | ALDH1A1 (0.41) | CNR2CNR1TRPA1TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025566-A1 | PEPTIDE-DRUG CONJUGATES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Københavns Universitet (DK) | 2025-01-23 | — | — | US | disclosed |
| CN-118510545-A | Peptide-drug conjugates for the treatment of neurodegenerative diseases | 哥本哈根大学 | 2024-08-16 | — | — | CN | disclosed |
| US-20210401776-A1 | METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2021-12-30 | — | — | US | disclosed |
| EP-3887481-A1 | A METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS | Zogenix International Limited (GB) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020112460-A1 | A METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS | ZOGENIX INTERNATIONAL LIMITED (GB) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401776-A1 | METHOD OF TREATING REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS | EPM2A, TPH1, TPH2 | CNR2 256/4885CNR1 452/4885TRPA1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.